MaximBio, a Maryland-based manufacturer specializing in lateral flow and diagnostic devices, today announced receipt of a $49.5 million award from the U.S. Department of Health and Human Services (HHS) through the Administration for Strategic Preparedness and Response (ASPR).
“This significant investment will enable us to maintain our U.S. operations for diagnostic test manufacturing. We are proud to be playing a crucial role in the nation’s response to the ongoing health crises and fortifying our defenses against potential future pandemics.”
Jonathan Maa, Chief Operating Officer at MaximBio
The award is part of a broader HHS initiative announced in September 2023 awarding $600 million to 12 domestic COVID-19 test manufacturers to strengthen the domestic supply chain.